Ownership history in UBS Group AG · 13 quarters on record
This page tracks every 13F SEC filing in which UBS Group AG reported a position in NEUROSENSE THERAPEUTICS LTD (NRSN). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price — sourced directly from SEC EDGAR 13F filings.
| Quarter | Action | Shares | Change | Chg % | % of Fund | Mkt Value | Price (EOQ) |
|---|---|---|---|---|---|---|---|
| 2025 Q4 | ADDED | 30,871 | +16,212 | +110.6% | 0.00% | $24K | $0.77 |
| 2025 Q3 | ADDED | 14,659 | +13,048 | +809.9% | 0.00% | $18K | $1.25 |
| 2025 Q2 | REDUCED | 1,611 | -664 | -29.2% | 0.00% | $3K | $1.89 |
| 2025 Q1 | REDUCED | 2,275 | -9,653 | -80.9% | 0.00% | $2K | $0.93 |
| 2024 Q1 | ADDED | 11,928 | +6,432 | +117.0% | 0.00% | $22K | $1.82 |
| 2023 Q4 | REDUCED | 5,496 | -4,169 | -43.1% | 0.00% | $4K | $0.79 |
| 2023 Q3 | ADDED | 9,665 | +4,903 | +103.0% | 0.00% | $7K | $0.71 |
| 2023 Q1 | ADDED | 4,762 | +697 | +17.1% | 0.00% | $8K | $1.72 |
| 2022 Q4 | ADDED | 4,065 | +2,238 | +122.5% | 0.00% | $5K | $1.22 |
| 2022 Q3 | REDUCED | 1,827 | -11,601 | -86.4% | 0.00% | $3K | $1.79 |
As of 2025 Q4 — sorted by position size